Exchange: NYSE·Updated 07:43 PM EDT
GSK logo

GSKGlaxosmithkline plc - ADR

$53.75
$2.36
(4.60%)
Today
Closed $53.66
$0.09
(0.17%)
After Hours
EarningsJul 28
Mkt Cap$102.77B
Vol3.8M
News
all
press releases
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.
Zacks
News Placeholder
GSK Commences Tender Offer To Acquire Nuvalent For $124 Per Share
(RTTNews) - GSK plc (GSK) said Wednesday that its indirect wholly-owned subsidiary, Harmony Row Acquisition Co., has commenced a tender offer to acquire all outstanding shares of Nuvalent Inc. (NUVL) for $124.00 per share in cash...
Nasdaq News: Markets
News Placeholder
Top Analyst Reports for Micron Technology, Coca-Cola & Arista Networks
MU, KO and ANET headline Zacks' latest analyst reports, with AI demand, pricing gains and networking expansion driving the outlook.
Zacks
News Placeholder
Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz
The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.
24-7 Market News
News Placeholder
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
Zacks
News Placeholder
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Zacks
News Placeholder
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii...
Business Wire
News Placeholder
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.read more...
Benzinga
News Placeholder
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.
Zacks
<
1
2
...
>

Advertisement|Remove ads.